Topic: Innovative Payment Models

  • Blueprints for Indication-Specific Pricing

    Blueprints for Indication-Specific Pricing

  • Pharmaceutical Products and Their Value

    Pharmaceutical Products and Their Value

  • Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

    Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

  • Abandon Biosimilars as Biologics are Natural Monopolies

  • Overview of Original Subscription Model and Features of LA and WA Proposals

    Overview of Original Subscription Model and Features of LA and WA Proposals

  • The “Netflix Model” of Financing Hepatitis C Treatment

    The “Netflix Model” of Financing Hepatitis C Treatment

  • Part B Payment for Medicare Drugs

    Part B Payment for Medicare Drugs

  • Do High Drug Prices Drive Innovation, Or Hurt It?